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Abstract 
Most gastric neuroendocrine tumours are well differentiated and considered as 
neuroendocrine neoplasms, whilst poorly differentiated lesions are considered as 
neuroendocrine carcinomas and account for only 6–16% of gastric neuroendocrine tumours. 
Gastric mixed adenoneuroendocrine carcinomas are rare malignancies usually composed of 
a neuroendocrine carcinoma and an adenocarcinoma with a variable grade of 
differentiation. Here, we report an unusual and rare gastric mixed adenoneuroendocrine 
carcinoma with a trilineage cell differentiation including a neuroendocrine carcinoma, an 
adenocarcinoma and a squamous cell carcinoma. A brief discussion of the histopathological 
features, biological behaviour and treatment of this rare tumour type is presented. 
 
Introduction 
Gastric neuroendocrine tumours (NETs) are usually well differentiated, non-
functioning neoplasms consisting of enterochromaffin-like (ECL) cells. Three distinct 
tumour types are recognised: (1) type I (74% of gastric NETs), associated with 
autoimmune chronic atrophic gastritis (A-CAG); (2) type II (6% of gastric NETs), 
associated with multiple endocrine neoplasia type 1 (MEN1) and Zollinger-Ellison 
syndrome (ZES), and (3) type III, sporadic (13% of gastric NETs), not associated with  
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A-CAG or MEN1/ZES. Of the three types of ECL cell NETs, type I and type II tumours are 
invariably associated with ECL cell hyperplasia [1] and hypergastrinaemia, resulting 
from a secondary response to antral gastrin cells to achlorydria in type I and from 
unregulated hormone release by a gastrinoma in type II. Type III tumours are sporadic, 
not associated with hypergastrinaemia or ECL cell hyperplasia. They are usually single 
lesions and often display more aggressive features than type I and type II tumours. Due 
to the difference in behaviour between the three types of NETs, type I and type II 
tumours are considered as neuroendocrine neoplasms, whilst type III tumours are 
mostly neuroendocrine carcinomas (NECs). 
Recently, to include all poorly differentiated gastric NETs which consist of other than 
ECL gastric endocrine cells (serotonin or gastrin producing) and also a very rare type of 
gastric malignancies, the mixed adenoneuroendocrine carcinomas (MANECs), another 
type, ‘type IV gastric NET’, has been suggested.  
Due to their rarity, our knowledge of gastric MANECs is limited and mainly based on 
a small series of patients and case reports. MANECs are a special type of tumour, 
characterised by an intimate mixture of two histologically different tumours, a NEC and 
a gland-forming carcinoma (adenocarcinoma). Both components are malignant.  
Here, we report an interesting case of a gastric MANEC composed of a NEC and an 
exocrine component with two different cell differentiations including a moderately 
differentiated adenocarcinoma and a squamous cell carcinoma, of which only the NEC 
component has metastasised to the liver. 
Case Description 
We report the case of an 81-year-old man who presented 4 months earlier to his local hospital 
with right hypochondrial pain, palpitations, diarrhoea up to 10 times daily, nausea, anorexia and 
weight loss. His past medical history included severe ischaemic cardiomyopathy and diabetes mellitus 
type II. A noncontrast CT scan of his abdomen revealed multiple liver lesions. An ultrasound-guided 
fine needle aspiration of one of these lesions was reported as ‘metastasis from NET’. Common tumour 
markers (CEA, CA 19-9) were not elevated. An 18F-FDG-PET scan revealed hypermetabolic areas in the 
liver, para-oesophageal, porta hepatis and para-aortic regions. The patient was referred to our 
hospital for further medical management. 
Upon arrival, he was treated aggressively for acute kidney injury due to dehydration and 
underwent a noncontrast staging CT scan of his chest, abdomen and pelvis. The scan showed a gastric 
tumour with hepatic, intra-abdominal and left supraclavicular lymph node metastases. No pulmonary 
metastases were observed.  
For further evaluation of the gastric lesion, the patient went on to have 
oesophagogastroduodenoscopy which revealed a large ulcerating malignant-looking mass in the 
antrum of the stomach (fig. 1), gastritis and duodenitis. The histology from the gastric mass showed a 
‘MANEC with a small area of squamous differentiation’. Neuroendocrine markers for chromogranin 
and synaptophysin were positive in the neuroendocrine component only and negative in the exocrine 
component of both adenocarcinoma and squamous cell carcinoma (fig. 2a–f). The tumour mitotic 
index was 52 mitoses per 10 high-power fields, and the Ki67 was 65%. Further biochemical and 
functional imaging work-up was carried out. The serum level of chromogranin A was 551 pmol/l 
(normal level <60 pmol/l), and the urine 5-HIAA level was 30 µmol/day (normal level 0–42 
µmol/day). 
In light of the neuroendocrine component, the patient underwent Indium-111 pentetreotide 
scinitgraphy (OctreoscanTM), which showed avid uptake in the hepatic lesions, stomach and in a para-
renal lymph node (fig. 3). On the basis of tumour biology and the disease extent, the patient would  
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have been a candidate for cytotoxic chemotherapy. However, due to his other comorbidities and poor 
performance status, he was commenced only on long-acting somatostatin analogues and best 
supportive/palliative treatment. Following this, the patient’s gastrointestinal symptoms partially 
improved and he was discharged back home.  
Discussion 
Gastrointestinal tumours displaying both exocrine and neuroendocrine 
differentiation are well recognised, although uncommon. Most of them arise in the 
appendix, but they also occur in the colon, stomach, oesophagus, duodenum and 
gallbladder. The association of the two components can vary in a spectrum ranging 
from nonendocrine neoplasms – either adenomas or carcinomas – with interspersed 
neuroendocrine cells to truly composite/mixed tumours showing an intimate mixture 
of neuroendocrine and exocrine tumour aggregates and to collision tumours in which 
the neuroendocrine neoplasm/carcinoma and the adenoma/adenocarcinoma are 
closely juxtaposed but not admixed [2]. Fujiyoshi et al. [3] reclassified mixed endocrine 
and nonendocrine epithelial tumours by dividing the tumours into six categories: (1) 
neuroendocrine cells interspersed within carcinomas; (2) carcinoids (NETs) with 
interspersed nonendocrine cells; (3) composite glandular-neuroendocrine cell 
carcinomas containing areas of carcinoid and conventional carcinomas; (4) collision 
tumours in which NETs and conventional carcinomas are closely juxtaposed but not 
admixed; (5) amphicrine tumours predominantly composed of cells exhibiting 
concurrent neuroendocrine and nonendocrine differentiation, and (6) combinations of 
the previous types. According to the World Health Organisation classification of 
tumours of the digestive system, tumours can be classified as truly mixed only if both 
components are present in significant proportions – at least 30% of either component 
should be identified to qualify for this definition [4]. In 2010, mixed exocrine-NECs 
have been renamed as MANECs by the World Health Organisation. 
Gastric MANECs are rare and usually described to be composed of an exocrine 
component represented by an adenocarcinoma with a variable grade of differentiation 
and a neuroendocrine component usually represented by a NEC and rarely a NET. The 
case reported here is a peculiar MANEC, displaying a trilineage cell differentiation 
including a NEC, an adenocarcinoma and a squamous cell carcinoma (fig. 2a,b). The 
three components are intimately intermingled, although all three phenotypes are well 
recognisable as three distinct histological tumours with three different 
immunophenotypes (fig. 2c–f). A very few cases of MANECs with a squamous cell 
carcinoma component have been previously described in the literature [5–7]. Due to 
their rarity, very little is known about their histogenesis. Interesting findings have been 
published by Furlan et al. [8], including 5 mixed endocrine-exocrine tumours (2 gastric 
and 3 colonic) and 1 rectal collision tumour studied using 35 polymorphic 
microsatellite markers. A close genetic relationship between the two distinct histologic 
components within mixed endocrine-exocrine tumours was found, supporting the 
hypothesis that a monoclonal mechanism of tumorigenesis was the most frequent 
genetic event in mixed exocrine-endocrine tumours. Clonal divergence was observed in 
the only collision tumour investigated, composed of a well differentiated endocrine 
carcinoma associated with an adenocarcinoma, confirming the existence of double 
tumours growing next to each other coincidentally but showing different histogenesis 
and different tumorgenetic pathways. Based on the findings of Furlan et al. [8], we can  
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postulate that our gastric MANEC, composed of three histologically distinct tumours 
but intimately mixed together, is most likely derived from a common pluripotent 
progenitor/stem cell. A few other authors have postulated the origin from a 
pluripotential precursor cell [6, 7, 9]. 
As for the histogenesis, the natural history of the gastric MANECs is also still unclear. 
In our case, the clinical behaviour seemed to depend on the NEC component. The fine 
needle aspiration of one of the liver lesions had demonstrated the neuroendocrine 
nature of the liver metastases, lately confirmed by the avid uptake on Octreoscan. Kim 
and Chae [10] have recently published similar findings: the NEC component of their 
gastric MANEC had shown more aggressive features, invading into the serosa and the 
lymphatic glands, whereas the glandular carcinoma was confined to the mucosa and 
submucosa. Volante et al. [11] reported that the clinical behaviour of composite 
carcinomas depends on the adenocarcinomatous component if the associated 
endocrine component is well differentiated and upon the neuroendocrine component if 
it is poorly differentiated.  
Treatment of localized gastric NECs usually involves total gastrectomy. In cases with 
distant metastases, combination of cisplatin and etoposide has been recommended 
[12]. Ideally, we would have commenced our patient on a platinum-based 
chemotherapy regimen. However, in view of the patient’s poor performance status, we 
started him on palliative treatment with long-acting somatostatin analogues. The 
patient improved and was able to be discharged home. 
In summary, we reported a peculiar gastric MANEC with trilineage cell 
differentiation (NEC + adenocarcinoma + squamous cell carcinoma), of which only the 
NEC component metastasised to the liver. As all MANECs seem to be very aggressive 
from the early beginning and platinum-based chemotherapy should be the first-choice 
treatment in advanced disease, there are no data to support the hypothesis that the 
presence of a third cell clone can have some implications to the overall behaviour of 
those tumours. 
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Fig. 1. Macroscopic appearance of the tumour in the stomach. 
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Fig. 2. Microscopic appearance of the MANEC tumour. a Moderately differentiated adenocarcinoma 
intimately admixed with a poorly differentiated neuroendocrine carcinoma. HE ×10. b Squamous cell 
carcinoma component admixed with the NEC component. Squamous ×10. c Positivity of the 
neuroendocrine component for chromogranin and negativity of the adenocarcinomatous component 
for chromogranin. Chromogranin ×20. d Negativity of the squamous cell carcinoma for chromogranin 
and positivity of the NEC for chromogranin. Chromo-squamous ×20. e Squamous cell differentiation 
as confirmed by the positivity for high molecular weight cytokeratins such as CK5. CK5-squamous 
×20. f Negativity of both the adenocarcinomatous component and the NEC component for CK5. CK5-
adeno-NEC. 
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Fig. 3. Indium-111 Octreoscan SPECT-CT, liver and stomach uptake. 
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